Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study in Healthy Men to Measure the Amount of BI 730357 in the Blood When Taken as a Tablet

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 730357
Drug: BI 730357 mixed with [C-14] BI 730357 BS

First Posted Date: 2019-01-15

Last Posted Date: 2023-07-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 6

Registration Number: NCT03804671

Locations: 🇳🇱
ICON, Groningen, Netherlands

A Study to Test How Food Influences the Amount of BI 1323495 in the Blood of Healthy Men

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1323495,

First Posted Date: 2019-01-14

Last Posted Date: 2024-02-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT03802331

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study in Healthy Men to Find Out How Well Different Doses of BI 764122 Are Tolerated and Whether Food Affects the Amount of BI 764122 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 764122
Drug: Placebo

First Posted Date: 2019-01-07

Last Posted Date: 2023-05-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 76

Registration Number: NCT03794323

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 730357 Are Taken up in the Body and How Well They Are Tolerated

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 730357
Drug: Placebo

First Posted Date: 2019-01-04

Last Posted Date: 2023-07-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT03793621

Locations: 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 730357 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 730357
Drug: Itraconazole

First Posted Date: 2018-12-20

Last Posted Date: 2023-07-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT03782987

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis

Phase 2

Completed

Conditions: Generalized Pustular Psoriasis

Interventions: Drug: Placebo
Drug: Spesolimab

First Posted Date: 2018-12-20

Last Posted Date: 2022-03-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 53

Registration Number: NCT03782792

Locations: 🇨🇳
Tianjin Medical University General Hospital, Tianjin, China
🇫🇷
HOP Robert Debré, Reims, France
🇹🇳
Hedi Chaker Hospital, Department of Dermatology, Tunisia, Tunisia

and more 34 locations

A Study in Healthy Men to Measure the Amount of BI 425809 in the Blood When Taken as a Tablet

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 425809
Drug: BI 425809 mixed with [C-14]-BI 425809

First Posted Date: 2018-12-20

Last Posted Date: 2019-03-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 6

Registration Number: NCT03783000

Locations: 🇳🇱
PRA Health Sciences Onderzoekscentrum Martini, Groningen, Netherlands

This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091

Phase 1

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung
Head and Neck Neoplasms

Interventions: Drug: BI 754111
Drug: [89Zr]Zr-BI 754111
Drug: BI 754091

First Posted Date: 2018-12-19

Last Posted Date: 2021-11-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 8

Registration Number: NCT03780725

Locations: 🇳🇱
Amsterdam UMC Locatie VUMC, Amsterdam, Netherlands

BI 705564 in Patients With Systemic Lupus Erythematosus (SLE)

Phase 1

Withdrawn

Conditions: Lupus Erythematosus, Systemic

Interventions: Drug: BI 705564
Drug: Placebo

First Posted Date: 2018-12-11

Last Posted Date: 2021-11-15

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT03771885

Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Empagliflozin
Drug: Dipeptidyl-peptidase 4 (DPP-4) inhibitors

First Posted Date: 2018-12-05

Last Posted Date: 2022-02-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1502

Registration Number: NCT03764631

Locations: 🇸🇦
Dr. Soliman Fakeeh Hospital, Jeddah, Saudi Arabia
🇸🇦
Shifa Hospital, Makkah, Saudi Arabia
🇸🇦
Prince Fahad bin Sultan hospital, Tabuk, Saudi Arabia

and more 18 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy